<DOC>
	<DOCNO>NCT01505413</DOCNO>
	<brief_summary>Erlotinib orally available , reversible tyrosine kinase inhibitor epidermal growth factor receptor ( EGFR ) . Association chemoresistance activity certain tyrosine kinase ( e.g . ErbB-1 Src ) describe pancreatic cancer make strong case combine gemcitabine tyrosine kinase inhibitor . In phase III trial , addition erlotinib gemcitabine improve survival compare gemcitabine alone advanced pancreatic cancer ( MJ Moor et al ) . Also , gemcitabine combination oxaliplatin superior gemcitabine alone term progression free survival response rate one phase III trial ( Louvet et al ) . Taken together , combine erlotinib gemcitabine oxaliplatin may improve overall survival clinical benefit advance pancreatic cancer .</brief_summary>
	<brief_title>Phase 2 Study Erlotinib , Gemcitabine Oxaliplatin Combination Chemotherapy Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Open , uncontrolled , multicenter , phase II study This study enroll previous chemo-naïve patient locally advance unresectable metastatic pancreatic cancer . Study regimen : - Erlotinib 100 mg po qd daily AND - Gemcitabine 1000 mg/m² 150mL normal saline intravenously infusion 100min Day 1 - Oxaliplatin 100 mg/m2 500mL 5DW intravenously 2-hour infusion D2 Every 2 week Each two week cycle . If end 12 cycle response continue , administer Gemcitabine erlotinib progression .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Age 18 year 2 . ECOG performance status ≤2 3 . Histologically confirm adenocarcinoma pancreas 4 . The disease Locally advance deem surgeon unresectable , metastatic disease . 5 . Prior chemotherapy permit , except fluorouracil give concurrently radiosensitizer . 6 . Patients must normal organ function evidence Number absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L Number thrombocyte &gt; 100 x 109/L Total bilirubin &lt; 1.5 x upper limit normal ( although patient Total bilirubin count 1.5 3 x upper limit normal decrease anticipate , ex . Biliary stent insertion ) ALAT , ASAT &lt; 3 x upper limit normal ( case liver metastasis , 5 x upper limit normal ) Alkaline phosphatase &lt; 3 x upper limit normal ( case liver metastasis , 5 x upper limit normal ) 7 . Pain controlled least two week without increase narcotic consumption . 8 . Biliary obstruction control least two week evident stable improve liver function test especially total bilirubin . 9 . Patient sign Patient Informed Consent Form . 10 . For female childbearing potential , negative pregnancy test must obtain within 72 hour start therapy . 11 . Is able take medication orally 12 . A patient least one measurable primary lesion diameter confirm 10mm spiral CT multidetector CT ( MD CT ) 20 mm longer conventional CT ( use consistent method study period ) 1 . Tumor type adenocarcinoma 2 . Evidence uncontrolled CNS disease ( patient control CNS disease 4 week use image method steroid eligible ) 3 . Uncontrolled Nausea Vomiting 4 . Diagnosis malignancy last 5 year exclude nonmelanoma skin cancer situ cervical cancer . 5 . Subjects unlikely comply protocol , e.g . uncooperative attitude , inability return follow visit unlikelihood complete study . 6 . Any known history hypersensitivity study drug . 7 . Pregnant lactating woman . 8 . Symptomatic peripheral sensory neuropathy ( NCI CTCAE v3.0 ≥ grade 2 ) 9 . Other serious illness medical condition , notably heart lung failure , active uncontrolled infection 10 . Prior radiotherapy administer target lesion select study , radiotherapy nontarget lesion complete within 4 week include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>advanced unresectable metastatic Pancreatic Cancer</keyword>
</DOC>